RecruitingPhase 3NCT06254469
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Studying Dementia pugilistica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CereMark Pharma, LLC
- Principal Investigator
- Chad Yucus, MDEndeavor Health System
- Intervention
- [F-18]Flornaptitril(drug)
- Enrollment
- 230 enrolled
- Eligibility
- 45 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- Endeavor Health Systems, Evanston, Illinois, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06254469 on ClinicalTrials.govOther trials for Dementia pugilistica
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07521384Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative TherapyHealing Hope International
- ENROLLING BY INVITATIONNCT06860828The DIAGNOSE CTE Research Project-IIBoston University
- RECRUITINGNCT07302503Pilot Study Evaluating brainQuant's Ability to Detect Alterations in White Matter in Diffusion MRI, Indicative of Post-traumatic LesionsUniversity Hospital, Strasbourg, France
- RECRUITINGNCT04124029Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)VA Office of Research and Development
- RECRUITINGNCT03218332Post-Concussion Syndrome in Professional Athletes: A Multidisciplinary StudyUniversity Health Network, Toronto